| 证券代码 | BRPAR.O |
| 证券名称 | Big Rock Partners Acquisition Corp Rt |
| 证券类型 | 美国权利 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2017-12-01 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | - |
| 公司名称 | NRX Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 2645 North Federal Highway, Suite 230, Delray Beach, Florida, USA |
| 成立日期 | 2017-09-18 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.neurorxpharma.com |
| 电话 | +1 (310) 734-2300 |
| 传真 | - |
| 公司简介 | NRX Pharmaceuticals, Inc. draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. |